(Date:1/7/2009)... 2009Dedicated to the memory and scientific accomp...fields of angiogenesis and vasculogenesis and shed...stic disease, the newly released special double is...and Biology includes a series of papers that refl...physician-scientists of his generation. Lymphatic...
(Date:1/7/2009)...ure for spinal muscular atrophy (SMA), a genetic d...s the leading genetic cause of infant death, but U...a new therapeutic target that improves deteriorati...herapy enhanced muscle strength, improved gross mo...el. , "This therapy does not directly target t...
(Date:1/7/2009)...uscle along the spinal column called the multifidu...a healthy back, according to researchers at the Un...ne. Their findings about the potentially importan...cle has been published on line in advance of the J...gery . , "The multifidus muscle was formerly th...
(Date:1/7/2009)...PRNewswire/ -- Americans can,t control the economy...hemselves about what they should pay for healthcar...ffort to provide free pricing data to consumers la...nformation they need to pay fair prices for health...ices, even within the same market and provider net...
Breaking Medicine News(10 mins):Health News:Festschrift Issue honoring Judah Folkman, M.D., in Lymphatic Research and Biology 2Health News:Researchers discover target that could ease spinal muscular atrophy symptoms 2Health News:Unique skeletal muscle design contributes to spine stability 2Health News:Healthcarebluebook.com: New Web Site Teaches How to Price Shop 2(Date:1/7/2009)..., BEIJING, Jan. 7 Tiantan Puhua H...hua.com ), the worldwide leader in using stem cell...ounced today six new globally experienced addition...ntly expand the hospital,s treatment capabilities ...ents. The six senior doctors include the distingui...
(Date:1/6/2009)..., NEW YORK, Jan. 6 The...t $2.7 million to four industry research teams for... for Parkinson,s disease. , , The funding was a...pment Initiative. This program, first launched in...rts on Parkinson,s research. TDI is part of MJFF...
(Date:1/5/2009)..., SAN DIEGO, Jan. 5 Cylene Pharma...Phase I clinical trial of its oral CK2 protein kin...solid tumors, Castleman,s disease, or multiple mye...ating trial are determination of safety, tolerance...propriate dose for Phase II trials. In addition, m...
(Date:12/29/2008)..., BETHESDA, Md., Dec. 29 /PRNewswire-USNewswire/ ...Human Research Protection was announced today by D...the Health Improvement Institute. , , The winn...xas M.D. Anderson Cancer Center -- for its best..." This program provides for 1) enhanced human sub...
Breaking Medicine Technology:Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2New Michael J Fox Foundation Initiative Will Drive Development of Web Based Tools to Increase Patient Participation in Parkinsons Clinical Trials 1562 1New Michael J Fox Foundation Initiative Will Drive Development of Web Based Tools to Increase Patient Participation in Parkinsons Clinical Trials 1562 2Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 1Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 2Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 3Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 1Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 2Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 3Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 4Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 5Spartan Stores Becomes Largest U S Supermarket Chain to Receive NSF Shop Fresh 28TM 29 Certification 14743 1Spartan Stores Becomes Largest U S Supermarket Chain to Receive NSF Shop Fresh 28TM 29 Certification 14743 2Spartan Stores Becomes Largest U S Supermarket Chain to Receive NSF Shop Fresh 28TM 29 Certification 14743 3...un 1, 2007 - A therapeutic,vaccine developed by th...mises new hope for cancer patients. The results of...resented to an,international audience at the Annua...Oncology (ASCO) in Chicago, USA. ASCO is the,most ...ialists,world-wide., The active substance VPM4001,...
... 1, 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, XSSE: OXGN...loping novel therapeutics to treat cancer and eye,...bstracts in the,2007 Annual Meeting program distri...American Society of Clinical Oncology (ASCO),in Ch...st time full data from a,randomized Phase II trial...
Other Medicine Technology:Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4Our popular Back-Aid Apron now comes standard with an improved Universal Back-Saver Belt that has firmer side supports to take more weight off your shoulders! Waist-hugging belt and back shoulder str
Hip-hugging design transfers weight from shoulders to the hips. Crisscross shoulder design provides snug and comfortable upper torso fit while preventing apron from slipping off shoulders.
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma.
Complete cytology platform.
Medicine Products: